SG11201507769SA - Polypeptide having sialylated sugar chains attached thereto - Google Patents

Polypeptide having sialylated sugar chains attached thereto

Info

Publication number
SG11201507769SA
SG11201507769SA SG11201507769SA SG11201507769SA SG11201507769SA SG 11201507769S A SG11201507769S A SG 11201507769SA SG 11201507769S A SG11201507769S A SG 11201507769SA SG 11201507769S A SG11201507769S A SG 11201507769SA SG 11201507769S A SG11201507769S A SG 11201507769SA
Authority
SG
Singapore
Prior art keywords
polypeptide
sugar chains
chains attached
sialylated sugar
sialylated
Prior art date
Application number
SG11201507769SA
Inventor
Masaki Ohuchi
Mika Nishihara
Katsunari Tezuka
Masatoshi Maeda
Yasuhiro Kajihara
Izumi Sakamoto
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc filed Critical Glytech Inc
Publication of SG11201507769SA publication Critical patent/SG11201507769SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201507769SA 2013-03-29 2014-03-24 Polypeptide having sialylated sugar chains attached thereto SG11201507769SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013073703 2013-03-29
PCT/JP2014/058127 WO2014157107A1 (en) 2013-03-29 2014-03-24 Polypeptide having sialylated sugar chains attached thereto

Publications (1)

Publication Number Publication Date
SG11201507769SA true SG11201507769SA (en) 2015-10-29

Family

ID=51624080

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507769SA SG11201507769SA (en) 2013-03-29 2014-03-24 Polypeptide having sialylated sugar chains attached thereto

Country Status (16)

Country Link
US (1) US10053499B2 (en)
EP (1) EP2982686B1 (en)
JP (1) JP6368706B2 (en)
KR (1) KR102186063B1 (en)
CN (1) CN104334574B (en)
AU (1) AU2014245917B2 (en)
BR (1) BR112015024423B1 (en)
CA (1) CA2908211C (en)
DK (1) DK2982686T3 (en)
ES (1) ES2687801T3 (en)
MY (1) MY171183A (en)
PH (1) PH12015502224A1 (en)
RU (1) RU2668163C2 (en)
SG (1) SG11201507769SA (en)
TW (1) TWI638830B (en)
WO (1) WO2014157107A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116064705A (en) * 2016-07-01 2023-05-05 第一三共株式会社 Method for preparing Fc-containing molecules with reconstituted sugar chains
JP6852397B2 (en) * 2016-12-28 2021-03-31 株式会社島津製作所 Preparation method and analysis method of analytical sample
WO2023145812A1 (en) * 2022-01-31 2023-08-03 株式会社日本触媒 Glycosylated protein having glucocerebrosidase activity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
IL130964A0 (en) 1997-01-16 2001-01-28 Cytel Corp Practical in vitro sialylation of recombinant glycoproteins
DE19717864C2 (en) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon beta, process for its preparation and its use
JP4574007B2 (en) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム Polyol-IFN-beta complex
EP1121156B1 (en) 1998-10-16 2006-02-22 Biogen Idec MA Inc. Polymer conjugates of interferon beta- 1a and their uses
BR9915548A (en) 1998-10-16 2001-08-14 Biogen Inc Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
ES2300280T3 (en) 1999-12-08 2008-06-16 Amgen Inc. MOLECULES OF INTERFERRED TYPE AND USES OF THE SAME.
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU7338501A (en) 2000-09-08 2002-03-22 Gryphon Sciences Polymer-modified synthetic proteins
ATE355087T1 (en) 2000-10-24 2006-03-15 Cis Bio Int STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS WITH A HYDROPHILIC THIOETHER OR A HYDROPHILIC 6-HYDROXY-CHROMANE
DE10104869A1 (en) 2001-02-03 2002-08-08 Cognis Deutschland Gmbh Additive for oil-based invert drilling fluids
BR0207576A (en) * 2001-02-27 2004-04-27 Maxygen Aps Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
KR20030084992A (en) 2001-03-15 2003-11-01 메르크 파텐트 게엠베하 Modified interferon beta with reduced immunogenicity
AUPR544401A0 (en) 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
WO2003008431A1 (en) 2001-06-19 2003-01-30 Otsuka Chemical Co.,Ltd. Process for producing sugar chain asparagine derivative
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
CA2477577A1 (en) 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US20040137581A1 (en) 2002-10-01 2004-07-15 Xencor Interferon variants with improved properties
US20040070046A1 (en) 2002-10-15 2004-04-15 Hiroaki Niimi Reliable dual gate dielectrics for MOS transistors
TWI330641B (en) 2002-12-24 2010-09-21 Yasuhiro Kajihara Sugar chain asparagine derivatives
KR100661212B1 (en) 2002-12-26 2007-04-16 오츠카 가가쿠 가부시키가이샤 Three-branched sugar-chain asparagine derivatives, the sugar-chain asparagines, the sugar chains, and processes for producing these
ES2701175T3 (en) 2003-02-04 2019-02-21 Glytech Inc Process to produce asparagine derivative of sugar chain
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
JP4607017B2 (en) 2003-07-28 2011-01-05 大塚化学株式会社 Aminated complex type sugar chain derivative and method for producing the same
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
WO2005084303A2 (en) 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
RU2392963C2 (en) 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Synthetic versions of hyperglycolised protease-resistive polypeptide, oral compositions and methods of using such versions
CA2576030A1 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
KR100781666B1 (en) 2004-11-02 2007-12-03 신영기 Human Interferon-beta Mutein
US20070011055A1 (en) 2005-07-05 2007-01-11 Netfire 1 Pty Ltd E-commerce with direct access to real-time inventory
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
CN102015761A (en) * 2007-06-19 2011-04-13 大塚化学株式会社 GLP-1 peptide having sugar chain attached thereto
CN102850442B (en) 2007-07-31 2014-07-30 株式会社糖锁工学研究所 Glycopeptide
JP2009242372A (en) * 2008-03-11 2009-10-22 Yokohama City Univ Erythropoietin derivative having uniform sugar chain structure
AU2009261441B2 (en) * 2008-06-17 2013-01-10 Glytech, Inc. Oligosaccharide chain added glp-1 peptide
CA2733362C (en) 2008-08-08 2016-10-18 Universiteit Gent Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof
HUE037238T2 (en) 2008-08-19 2018-08-28 Glytech Inc Glycoprotein production method and screening method
WO2012051615A1 (en) * 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
SG193377A1 (en) * 2011-03-10 2013-10-30 Glytech Inc Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
WO2013002330A1 (en) * 2011-06-29 2013-01-03 協和発酵キリン株式会社 Method for purifying protein
IN2014CN02982A (en) 2011-10-01 2015-07-03 Glytech Inc

Also Published As

Publication number Publication date
CN104334574B (en) 2020-01-14
AU2014245917B2 (en) 2017-09-28
JP6368706B2 (en) 2018-08-01
US10053499B2 (en) 2018-08-21
BR112015024423A2 (en) 2017-07-18
RU2015146509A (en) 2017-05-10
KR20150139411A (en) 2015-12-11
DK2982686T3 (en) 2018-10-08
WO2014157107A1 (en) 2014-10-02
EP2982686A1 (en) 2016-02-10
AU2014245917A1 (en) 2015-09-24
EP2982686A4 (en) 2016-10-26
PH12015502224B1 (en) 2016-02-01
BR112015024423B1 (en) 2023-04-25
EP2982686B1 (en) 2018-06-27
PH12015502224A1 (en) 2016-02-01
JPWO2014157107A1 (en) 2017-02-16
KR102186063B1 (en) 2020-12-03
TWI638830B (en) 2018-10-21
RU2668163C2 (en) 2018-09-26
ES2687801T3 (en) 2018-10-29
TW201518318A (en) 2015-05-16
US20160052987A1 (en) 2016-02-25
CA2908211A1 (en) 2014-10-02
CN104334574A (en) 2015-02-04
MY171183A (en) 2019-09-30
CA2908211C (en) 2022-07-19

Similar Documents

Publication Publication Date Title
HK1221655A1 (en) Sialylated glycoproteins
PL2983511T3 (en) Improved sweetener
EP2989885A4 (en) Combine
PL2983510T3 (en) Improved sweetener
PL2981176T3 (en) Novel confectionary with improved crispiness
SG11201508032RA (en) (sugar chain)-polypeptide complex
EP3058084A4 (en) Sialylated glycoproteins
EP2989411A4 (en) Armour
GB201302863D0 (en) The Instaponytail
SG11201507769SA (en) Polypeptide having sialylated sugar chains attached thereto
SG11201510197RA (en) Connecting Mechanism
TWM476189U (en) Fastening type connector
SG2013090378A (en) Flexible vision inspector
GB201314945D0 (en) Protein crystals
GB201316975D0 (en) egg cracker
SG2013065297A (en) Chain structure
AU353919S (en) Confectionery
AU353918S (en) Confectionery
AU353917S (en) Confectionery
AU353920S (en) Confectionery
AU353921S (en) Confectionery
AU353914S (en) Confectionery
AU353915S (en) Confectionery
AU353922S (en) Confectionery
AU353913S (en) Confectionery